MedTrace Logo

Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

NCT01415895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2021-04-14

No results posted yet for this study

Summary

The study includes back pain of the cervical, thoracic, and the lumbar regions.

Conditions

Interventions

DRUG

Naltrexone and Clonidine Combination

subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.

DRUG

placebo

subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.

Sponsors & Collaborators

  • Annette C. Toledano MD

    lead INDUSTRY

Principal Investigators

  • Annette C Toledano, MD · Allodynic Therapeutics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01415895 on ClinicalTrials.gov